Theragnostics is a radiopharmaceutical company focused on developing new diagnostics and therapeutics for the oncology market. Our mission is to drive innovation in the fight against cancer by enhancing patients’ lives with precision radiopharmaceuticals. Our lead drugs are radiolabeled PARP inhibitors where we can bring radioactive decay directly to the DNA.
Our therapeutic is entering a Phase 1 trial where we are combining our PARPi with 123I to use the power of Auger emissions to treat cancers. Auger emissions have not been used as a therapeutic to date, however, with our drug binding directly to the DNA, we can use the power of Auger emission to kill cancer cells while also having a better safety profile compared to other leading radiopharmaceutical therapeutics that use Alpha or Beta emissions.
Theragnostics received FDA approval in February 2022 for NephroScanTM, Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA). In 2021, Theragnostics out licensed it’s single step PSMA kit IP to AAA/Novartis for their product LOCOMETZ®.
Please visit our booth, #8048, if you are interested in learning more about Theragnostics, our pipeline or NephroScan.